Skip to main content

Table 2 Detailed clinical profiles of RS3PE patients with malignancy

From: bFGF could be a biomarker of malignancy in RS3PE syndrome: an ambispective single-center cohort analysis of 51 patients

No. Age/sex Type of malignancy Time from arthritis onset to malignancy confirmation Signs ESR (mm/h) CRP (mg/L) bFGF (ng/mL) Initial pred. (mg/day) Response to pred.
1 85/M Acute myeloid leukemia -M2 6 months Unilateral hands 29 16.9 25.04 0 /
2 75/F Multiple myeloma
(IgA, λ)
2 years Bilateral hands 61.2 70 24.35 15 poor
3 80/M Diffuse large B cell lymphoma 2 months Bilateral hands 86 45.9 10.2 40 poor
4 53/M Plasma cell leukemia 8 months Unilateral hands 19 177.3 42.48 30 poor
5 85/F Rectal carcinoma 3 years No hands 44 10.4 17.58 30 poor
6 66/F Multiple myeloma 3months Bilateral hands 71 26.11 10.94 15 good
7 83/M Non-Hodgkin lymphoma 2 months Bilateral hands 67 101 5.57 15 good
8 73/M Lung carcinoma 2 years bilateral hands 5 9.39 6.63 7.5 good
  1. RS3PE remitting seronegative symmetrical synovitis with pitting edema, CRP C-reactive protein, ESR erythrocyte sedimentation rate, Pred. prednisolone